These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 24526500)

  • 1. Long time clinical outcomes of limus-eluting stent versus paclitaxel-eluting stent in patients undergoing percutaneous coronary artery intervention: A meta-analysis of randomized controlled clinical trials.
    Gao L; Hu X; Hou Y; Xue Q
    Cardiol J; 2014; 21(3):211-9. PubMed ID: 24526500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials.
    Planer D; Smits PC; Kereiakes DJ; Kedhi E; Fahy M; Xu K; Serruys PW; Stone GW
    JACC Cardiovasc Interv; 2011 Oct; 4(10):1104-15. PubMed ID: 22017936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of everolimus-eluting stent versus zotarolimus-eluting stent: A meta-analysis of randomized controlled clinical trials and observational studies.
    Gu H; Hua K; Li W; Wang Y; Yang J
    Int J Cardiol; 2015 Dec; 201():552-60. PubMed ID: 26334379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of everolimus and zotarolimus-eluting stents versus first-generation drug-eluting stents in patients with diabetes: A meta-analysis of randomized trials.
    Bavishi C; Baber U; Panwar S; Pirrotta S; Dangas GD; Moreno P; Tamis-Holland J; Kini AS; Sharma SK
    Int J Cardiol; 2017 Mar; 230():310-318. PubMed ID: 28062139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Everolimus- Versus Sirolimus-Eluting Stents: 5-Year Results From SORT OUT IV.
    Jensen LO; Thayssen P; Christiansen EH; Maeng M; Ravkilde J; Hansen KN; Hansen HS; Krusell L; Kaltoft A; Tilsted HH; Berencsi K; Junker A; Lassen JF;
    J Am Coll Cardiol; 2016 Feb; 67(7):751-62. PubMed ID: 26892409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
    Caixeta A; Lansky AJ; Serruys PW; Hermiller JB; Ruygrok P; Onuma Y; Gordon P; Yaqub M; Miquel-Hebert K; Veldhof S; Sood P; Su X; Jonnavithula L; Sudhir K; Stone GW;
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1220-8. PubMed ID: 21232715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis.
    Palmerini T; Biondi-Zoccai G; Della Riva D; Mariani A; Sabaté M; Valgimigli M; Frati G; Kedhi E; Smits PC; Kaiser C; Genereux P; Galatius S; Kirtane AJ; Stone GW
    J Am Coll Cardiol; 2013 Aug; 62(6):496-504. PubMed ID: 23747778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus-eluting stent is superior to paclitaxel-eluting stent for coronary intervention in patients with renal insufficiency: Long-term clinical outcomes.
    Ann SH; Seo SM; Kim PJ; Koh YS; Her SH; Shin DI; Park HJ; Park CS; Lee JM; Kim DB; Chang K; Chung WS; Seung KB
    Cardiol J; 2016; 23(6):637-646. PubMed ID: 27665858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.
    Palmerini T; Biondi-Zoccai G; Della Riva D; Mariani A; Sabaté M; Smits PC; Kaiser C; D'Ascenzo F; Frati G; Mancone M; Genereux P; Stone GW
    J Am Coll Cardiol; 2014 Feb; 63(4):299-307. PubMed ID: 24211507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
    Kereiakes DJ; Sudhir K; Hermiller JB; Gordon PC; Ferguson J; Yaqub M; Sood P; Su X; Yakubov S; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1229-39. PubMed ID: 21232716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: the Bern-Rotterdam diabetes cohort study.
    Simsek C; Räber L; Magro M; Boersma E; Onuma Y; Stefanini GG; Zanchin T; Kalesan B; Wenaweser P; Jüni P; van Geuns RJ; van Domburg RT; Windecker S; Serruys PW
    Int J Cardiol; 2013 Dec; 170(1):36-42. PubMed ID: 24196314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
    Xu B; Yang Y; Yuan Z; Du Z; Wong SC; Généreux P; Lu S;
    JACC Cardiovasc Interv; 2013 Jul; 6(7):664-70. PubMed ID: 23523240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus-eluting stents versus sirolimus- or paclitaxel-eluting stents: two-year results from the Guthrie Health Off-Label Stent (GHOST) registry.
    Harjai KJ; Kondareddy S; Pinkosky B; Harjai N; Orshaw P; Boura J
    J Interv Cardiol; 2013 Apr; 26(2):153-62. PubMed ID: 23363439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy outcomes of overlapping second-generation everolimus-eluting stents versus first-generation drug-eluting stents.
    Kitabata H; Loh JP; Pendyala LK; Badr S; Dvir D; Barbash IM; Minha S; Torguson R; Chen F; Satler LF; Suddath WO; Kent KM; Pichard AD; Waksman R
    Am J Cardiol; 2013 Oct; 112(8):1093-8. PubMed ID: 23827397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
    Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
    Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention).
    Taniwaki M; Stefanini GG; Silber S; Richardt G; Vranckx P; Serruys PW; Buszman PE; Kelbaek H; Windecker S;
    J Am Coll Cardiol; 2014 Apr; 63(16):1617-25. PubMed ID: 24530680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of five randomized clinical trials comparing sirolimus- versus paclitaxel-eluting stents in patients with diabetes mellitus.
    Zhang F; Dong L; Ge J
    Am J Cardiol; 2010 Jan; 105(1):64-8. PubMed ID: 20102892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.